Ultragenyx Pharmaceutical Inc. (RARE) · Oct 14, 2026 · Disposition
$203M PRV sale — $203M cash payable at closing
Ultragenyx’s PRV sale brings in $203 million of potential cash as newly approved FAYUVI moves toward commercialization, subject to closing.
Ultragenyx is moving from rare-disease development into commercialization, with newly approved FAYUVI positioned as the first FDA-approved treatment for Sanfilippo syndrome Type A and commercial shipments expected within 30–60 days. This filing monetizes a non-core regulatory asset while that launch gets underway. The company agreed to sell the Rare Pediatric Disease Priority Review Voucher earned with FAYUVI approval for $203 million in cash.
The cash is incremental funding, not operating revenue. It gives Ultragenyx additional non-dilutive capital during a period when it is launching FAYUVI and advancing a broader rare-disease pipeline, but the filing does not specify whether proceeds will fund commercialization, research, debt reduction, or general corporate purposes. The business benefit is therefore financial flexibility rather than a change to FAYUVI’s clinical or commercial outlook.
The headline amount is not yet cash in hand. Closing remains conditional on customary requirements, including expiration or termination of the Hart-Scott-Rodino waiting period. 〔0〕 There is no published consensus benchmark for this type of asset sale; versus the standing expectation that the voucher could be monetized after FAYUVI approval, the new information is the agreed $203 million price and the path to cash realization.
Bottom line: This is a modestly positive financing event for Ultragenyx’s commercialization and pipeline effort, but it does not alter the core FAYUVI launch story. Its value is mainly the added non-dilutive cash, assuming the transaction closes.
PRV closing after HSR waiting period
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!